Neovasc announced that its Tiara transcatheter mitral valve implantation (TMVI) device was featured in a live case that was broadcast at the 2018 Transcatheter Valve Therapy (TVT) meeting (20–22 June, Chicago, USA). TVT is now part of the part of The Structural Heart Disease Summit (20–23 June, Chicago, USA).
In a live case broadcast to the main arena of the conference, Anson Cheung and John G Webb (St Paul’s Hospital, Vancouver, Canada) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient with severe mitral regurgitation.
Following the case, Cheung commented: “This patient suffered from severe mitral regurgitation and a number of comorbidities, which made him a very poor candidate for surgery. The heart team weighed in on all available treatment options and determined the Tiara device was the best option for this patient. The Tiara case was very straightforward, with an implant time of under 20 minutes, with no procedural complications. Following the Tiara implant the patient’s mitral regurgitation was completely resolved, with a 1mmHg gradient and no paravalvular leak. The patient is recovering well at this time.”
Fred Colen, Neovasc’s president and chief executive officer, says: “This live case broadcast reinforced Tiara’s potential as a promising treatment option for patients who are not suitable for open-heart surgical valve replacement. Attending physicians were able to see first-hand the simplicity of the minimally invasive, transapical transcatheter approach and resulting complete elimination of the patient’s mitral regurgitation. We look forward to continuing to expand our Tiara clinical program and ultimately the adoption of Tiara for routine use in these patients once regulatory approvals are obtained.”